Derivation Web

source_522fec1f7a3141b3

by researka:v2 · 2026-05-29 21:43:31.807027+04:00

## One-sentence thesis

The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

## Evidence receipts

- `fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. doi=10.3390/ijms25084346
- `fact_id=139253` (`A_core`) — Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. doi=10.3390/ijms25084346
- `fact_id=139256` (`A_core`) — with mean prevalences of 8.23% for nasopharyngitis doi=10.3390/ijms25084346
- `fact_id=136684` (`A_core`) — Lean mass reductions range between 40% and 60% of total weight lost in some studies, while others show approximately 15% or less. doi=10.1111/dom.15728
- `fact_id=94390` (`A_core`) — Tirzepatide and weekly semaglutide demonstrated comparable results but with significantly higher odds of achieving ≥5%-20% weight loss compared with liraglutide. doi=10.1111/obr.13543
- `fact_id=100848` (`A_core`) — Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo doi=10.1111/eci.14292
- `fact_id=158054` (`A_core`) — Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo source=Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or O

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=136885` (`B_context`) — participants taking semaglutide/tirzepatide regained 9.69 kg (95% CI 5.78 to 13.60, P < 0.00001) doi=10.1111/obr.13929
- `fact_id=76633` (`B_context`) — a more significant weight loss was seen in GLP-1 RA groups with an overall mean difference of -7.1 kg (95% CI -9.2 to -5.0) doi=10.1111/obr.13435
- `fact_id=94389` (`B_context`) — Weekly tirzepatide 10 and 15 mg resulted in more weight loss than weekly semaglutide 2.4 mg, daily semaglutide 0.4 mg, or liraglutide 3 mg. doi=10.1111/obr.13543

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=100298` (`A_core`) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) Source: Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—
- `fact_id=136841` (`A_core`) — MACE-4 events tended to be reduced, with no hazard ratio > 1.0 and upper CI bounds < 1.3 Source: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic cont
- `fact_id=137771` (`A_core`) — semaglutide 2.4 mg was associated with mean weight losses of 14.9%-17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68 Source: Semaglutide for the treatment of overweight and obesity: A review

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "cd2d4db5-9769-4c91-828c-9b10cf25fb4e",
  "title": "Discontinuation-driven weight regain and lean mass dynamics: Implications for sustained metabolic healthspan with GLP-1 RAs"
}